NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
The final guidance publication comes following an appeal against earlier draft recommendations
Read More
Tag: Vyndaqel
Vyndaqel first treatment approved in Europe for ATTR-CM
The decision was based on results from the Phase III ATTR-ACT study.
Read More
Pfizer’s Vyndaqel, Vyndamax win US nod for rare disease
The approval is based on a clinical trial which showed that after an average of 30 months, the survival rate was higher in the Vyndaqel group.
Read More
Pfizer’s Vyndaqel slows neurodegenerative disease, analysis shows
A new analysis of data pooled from three clinical trials backs early intervention with Pfizer’s Vyndaqel in patients with the rare neurodegenerative disease transthyretin familial amyloid polyneuropathy (TTR-FAP).
Read More
- Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
- European approval enables measles protection with CSL’s immunoglobulin Privigen
- JJP Biologics reports positive interim phase 1b data for nebaprubart
- Immunotherapy boost can spare more bladder cancer patients major surgery
- Deep Science Ventures and MDC partner to accelerate brain treatments
